Royal Bank of Canada Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $161.00

Sarepta Therapeutics (NASDAQ:SRPT) had its target price reduced by research analysts at Royal Bank of Canada from $165.00 to $161.00 in a report issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s price target suggests a potential upside of 50.82% from the company’s current price.

Several other equities analysts also recently issued reports on the company. Guggenheim boosted their price objective on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Robert W. Baird reduced their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Needham & Company LLC reiterated a “buy” rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday. Evercore ISI reduced their price objective on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Finally, HC Wainwright restated a “sell” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a research report on Thursday. One research analyst has rated the stock with a sell rating, three have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $173.52.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT opened at $106.75 on Thursday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a 50 day simple moving average of $115.89 and a 200-day simple moving average of $122.61. The company has a market cap of $10.20 billion, a PE ratio of 85.40 and a beta of 0.75. Sarepta Therapeutics has a 12-month low of $101.00 and a 12-month high of $173.25.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares of the company’s stock, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares in the company, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new position in shares of Sarepta Therapeutics in the fourth quarter worth $244,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Sarepta Therapeutics by 11.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 299,301 shares of the biotechnology company’s stock worth $36,392,000 after acquiring an additional 31,098 shares during the last quarter. Woodline Partners LP acquired a new position in shares of Sarepta Therapeutics in the fourth quarter worth $5,713,000. Vestal Point Capital LP acquired a new position in shares of Sarepta Therapeutics in the fourth quarter worth $30,398,000. Finally, Vident Advisory LLC acquired a new position in shares of Sarepta Therapeutics in the fourth quarter worth $357,000. 86.68% of the stock is owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.